Ethosuximide – 500 mg

Brand:
Cayman
CAS:
77-67-8
Storage:
-20
UN-No:
Non-Hazardous - /

Ethosuximide is an anticonvulsant.{36303,36304,36305,36306,36307} It increases glucose, fructose-1,6-bisphosphate, and pyruvate levels in rat brain when administered at a dose of 200 mg/kg.{36303} Ethosuximide (400 mg/kg) reduces the severity of audiogenic seizures in a rat model of barbiturate withdrawal-induced convulsions.{36304} It also inhibits tonic hindlimb extension induced by pentylenetetrazole (PTZ; Item No. 18682) or brainstem stimulation (ED50s = 35 and 70 mg/kg, respectively), as well as leptazol-induced clonic seizures (ED50 = 230 mg/kg), in rats.{36305,36306} Ethosuximide reduces resting tremor by 60% in a macaque model of Parkinson’s disease induced by MPTP when administered at a dose of 150 mg/animal for 5 days.{36307} Formulations containing ethosuximide have been used in the treatment of petit mal seizures.  

 

Available on backorder

SKU: 23947 - 500 mg Category:

Description

An anticonvulsant; increases glucose, fructose-1,6-bisphosphate, and pyruvate levels in rat brain at 200 mg/kg; reduces the severity of audiogenic seizures in a rat model of barbiturate withdrawal-induced convulsions at 400 mg/kg; inhibits PTZ- or brainstem stimulation-induced tonic hindlimb extension (ED50s = 35 and 70 mg/kg, respectively), as well as leptazol-induced clonic seizures (ED50 = 230 mg/kg), in rats; reduces resting tremor by 60% in a macaque model of Parkinson’s disease induced by MPTP when administered at a dose of 150 mg/animal


Formal name: 3-ethyl-3-methyl-2,5-pyrrolidinedione

Synonyms:  CI-366|NSC 64013

Molecular weight: 141.2

CAS: 77-67-8

Purity: ≥95%

Formulation: A solid


Product Type|Biochemicals||Research Area|Neuroscience|Behavioral Neuroscience|Addiction Research||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease||Research Area|Neuroscience|Seizure Disorders